NK, T, dendritic and iNKT cells cultured separately, infused together
Quick answer
KEYCELL-IM inj. is EHL Bio's immune cell therapy: NK, T, dendritic and iNKT cells are separated from the patient's own blood, each activated and expanded with proprietary culture technology, cryopreserved, then expanded for infusion. Its selling point is that a single apheresis collection yields roughly 30 times more cells than a standard blood draw, enough for 6-12 doses.
Immunity has an innate arm (macrophages, NK cells, granulocytes) and an adaptive arm (B and T cells), with dendritic and gamma-delta T cells presenting antigen to bridge the two.
The concept is combination: dendritic cells present tumour antigen, T lymphocytes and NK cells attack abnormal cells, and iNKT cells boost overall immune activity — unlike older single-cell-type approaches.
The company says culturing each type separately keeps the dose composition consistent, unlike mixed culture where ratios drift. Its NK cell programme for lung cancer has completed preclinical study.
Important context: this class of cell immunotherapy is adjunctive alongside standard treatment such as surgery, chemotherapy or radiotherapy — not a replacement — and belongs under oncologist supervision.
No. It should complement the oncologist's plan; abandoning standard therapy for cells alone carries very high risk.
It is machine-based blood component separation during a draw, taking about 2-4 hours. Mild tingling from the anticoagulant is common and manageable during the session.
Typically in the post-primary-treatment setting to reduce recurrence risk, or as an adjunct where the physician judges it appropriate — not for every stage or cancer type.
Doses generally must be given at a licensed facility, so travel per scheduled cycle is required; plan the timetable and budget in advance.
5 points • reviewed 2026-08-28
Reviewed and last updated: 2026-08-28
10 sources • every claim is traceable
https://www.ehlbio.co.kr/company/about/
https://www.ehlbio.co.kr/company/history/
https://www.ehlbio.co.kr/rd/gmp/
https://www.ehlbio.co.kr/rd/institute/
https://www.ehlbio.co.kr/rd/patent/
https://www.ehlbio.co.kr/conditioned/
https://www.ehlbio.co.kr/immune_cell/
https://www.ehlbio.co.kr/cure/index/
https://www.ehlbio.co.kr/company/contact/
https://www.ehlbio.co.kr/rd/freezing/
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Cell drug pipeline · Joints & immunity